Valeant Pharmaceuticals (VRX) is changing its name to Bausch Health and the stock is a buy, according to TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer.

Cramer pointed to the recent successful track record of CEO Joe Papa, which includes paying down debt and solving various lawsuits.

For exclusive investing insight from Jim Cramer, get 24/7 access to Jim's charitable trust portfolio with a free trial to Action Alerts PLUS!